Journal
JOURNAL OF IMMUNOLOGY
Volume 171, Issue 8, Pages 3941-3946Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.171.8.3941
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI-47756] Funding Source: Medline
Ask authors/readers for more resources
Tumor cells are typically poorly immunogenic. The same mechanisms that evolved to avoid the induction of immune responses against self tissues, and, hence, autoimmune disease, also have to be overcome for immune therapy of cancer. Toll-like receptor-activating microbial products such as CpG motif containing DNA are among the primary stimuli that the immune system uses to distinguish between infectious nonself (that is to be attacked) and noninfectious self (that must not be attacked). We tested in a murine RMA lymphoma/C57BL/6 model whether providing the infectious nonself context in a tumor-by injecting CpG-oligode-oxynucleotides directly into the tumor-would elicit a protective antitumor response. Complete remission of established solid tumors Was achieved in immune competent mice, but not in T cell/B cell-deficient RAG-1 knockout mice. Intratumor injection of CpG-oligodeoxynucleotides was shown to induce a tumor-specific CD4(+) and CD8(+) T cell response of the type I effector class, and T cells adoptively transferred the protection to RAG-1 knockout mice. The data show that intratumor injection of CpG-oligodeoxynucleotides is a promising strategy for rendering tumors immunogenic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available